Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
RFS Pharma, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have completed Study RFSP-AMDX-2010 and received treatment with amdoxovir (500 mg bid or 300 mg bid) for 12 weeks before entry into study RFSP-AMDX-2012.
Must have maintained ≥ 1.0 log10 copies/mL from baseline at Week 12 in Study RFSP-AMDX-2010.
Must not have had any serious adverse experience since enrollment in Study RFSP-AMDX-2010, whether or not considered to be study drug-related.
You may not be if
Subjects who require ongoing therapy of nephrotoxic drugs or competitors of renal excretion.
Subjects who require therapy with hematologic, bone marrow suppressive or cytotoxic agents.
Subjects who require medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with life-threatening adverse events.
Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations.
